logo
Plus   Neg
Share
Email

Affimed (AFMD) Has Jumped To A New High On Genentech Deal

Affimed (AFMD) announced Tuesday morning that it has entered into a strategic collaboration agreement with Genentech. Under the terms of the deal, Affimed will receive an upfront payment of $96 million and is eligible for up to an additional $5.0 billion.

Affimed has gapped open sharply higher this morning and is now up 2.55 at $4.15 on strong volume. The stock has leaped to a new high for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

Follow RTT